“`html

New Treatments ⁣for Aggressive Bladder Cancer⁤ Receive Dutch Approval

Published: 2026/02/06

Teh Dutch Healthcare Institute (Zorginstituut Nederland) has advised including nogapendekin alfa inbakicept (Anktiva) and aumolertinib ⁣(Aumseqa) on the list of reimbursed ⁤medications. These⁢ drugs, approved‍ by the European ⁢Medicines Agency (EMA) in December 2025, meet the⁤ criteria for inclusion due to their potential to address significant unmet ⁤medical needs.

Nogapendekin Alfa ⁢Inbakicept: A New Hope for BCG-Resistant Bladder Cancer

Nogapendekin alfa inbakicept, in combination with Bacillus Calmette-Guérin (BCG), is indicated for the treatment of⁢ BCG-resistant non-muscle invasive bladder cancer (NMIBC) with ‍carcinoma in situ (CIS), ⁣with⁣ or without ⁤papillary tumors. BCG-resistance represents a major challenge ⁤in NMIBC treatment, often leading to disease progression and the⁤ need for cystectomy (bladder removal) [[1]]. This new combination therapy offers a potential option for patients who have exhausted standard treatment options.

The ⁤cost of nogapendekin